Earnings Releases·Nov 5, 2026, 4:09 PM ET

Mobia Medical — Third Quarter 2026 Earnings Summary

Revenue surged 73% year-over-year to $15.6 million, while gross profit rose 81% to $13.0 million, expanding gross margin to 83.2% from 79.6% in the prior year period.
Full-year 2026 revenue guidance was raised to $57.0–$57.5 million, implying 78–79% growth over 2025, driven by broader adoption of the Vivistim System and an increase in active territories to 40.
Net loss widened to $17.3 million ($0.52 per share) compared to $11.4 million ($13.31 per share) in Q3 2025, primarily due to a significant increase in weighted-average shares outstanding following the IPO and a 71% rise in operating expenses.
The company reported a strengthened balance sheet with cash and cash equivalents reaching $160.7 million as of September 30, 2026, up from $33.6 million at year-end 2025.